IGM Biosciences

General Information


We are a biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer patients. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to cancer cells than comparable IgG antibodies. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines.

Employees: 51
Founded: 1993
Contact Information
Address 325 E. Middlefield Road, Mountain View, CA 94043, US
Phone Number (650) 965-7873
Web Address http://www.igmbio.com
View Prospectus: IGM Biosciences
Financial Information
Market Cap $462.3mil
Revenues $0 mil (last 12 months)
Net Income $-33.7 mil (last 12 months)
IPO Profile
Symbol IGMS
Exchange NASDAQ
Shares (millions): 10.9
Price range $16.00 - $16.00
Est. $ Volume $175.0 mil
Manager / Joint Managers Jefferies/ Piper Jaffray/ Stifel/ Guggenheim Securities
CO-Managers -
Expected To Trade: 9/18/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change